IRLAB Therapeutics AB (publ) (IRLAB-A) - Net Assets
Based on the latest financial reports, IRLAB Therapeutics AB (publ) (IRLAB-A) has net assets worth Skr30.72 Million SEK (≈ $3.31 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr138.21 Million ≈ $14.87 Million USD) and total liabilities (Skr107.49 Million ≈ $11.57 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IRLAB Therapeutics AB (publ) tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr30.72 Million |
| % of Total Assets | 22.23% |
| Annual Growth Rate | 1.73% |
| 5-Year Change | -92.31% |
| 10-Year Change | -70.43% |
| Growth Volatility | 81.8 |
IRLAB Therapeutics AB (publ) - Net Assets Trend (2013–2025)
This chart illustrates how IRLAB Therapeutics AB (publ)'s net assets have evolved over time, based on quarterly financial data. See IRLAB-A defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for IRLAB Therapeutics AB (publ) (2013–2025)
The table below shows the annual net assets of IRLAB Therapeutics AB (publ) from 2013 to 2025. For live valuation and market cap data, see how much is IRLAB Therapeutics AB (publ) worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr30.72 Million ≈ $3.31 Million |
-5.87% |
| 2024-12-31 | Skr32.63 Million ≈ $3.51 Million |
-71.81% |
| 2023-12-31 | Skr115.76 Million ≈ $12.46 Million |
-60.20% |
| 2022-12-31 | Skr290.83 Million ≈ $31.30 Million |
-27.20% |
| 2021-12-31 | Skr399.48 Million ≈ $42.99 Million |
+14.83% |
| 2020-12-31 | Skr347.88 Million ≈ $37.44 Million |
+91.32% |
| 2019-12-31 | Skr181.83 Million ≈ $19.57 Million |
-14.42% |
| 2018-12-31 | Skr212.48 Million ≈ $22.87 Million |
+37.08% |
| 2017-12-31 | Skr155.00 Million ≈ $16.68 Million |
+49.20% |
| 2016-12-31 | Skr103.89 Million ≈ $11.18 Million |
+12.89% |
| 2015-12-31 | Skr92.03 Million ≈ $9.90 Million |
+3.90% |
| 2014-12-31 | Skr88.57 Million ≈ $9.53 Million |
+254.41% |
| 2013-12-31 | Skr24.99 Million ≈ $2.69 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to IRLAB Therapeutics AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 77138100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr1.70 Million | 5.53% |
| Other Components | Skr800.41 Million | 2605.66% |
| Total Equity | Skr30.72 Million | 100.00% |
IRLAB Therapeutics AB (publ) Competitors by Market Cap
The table below lists competitors of IRLAB Therapeutics AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Euro Manganese Inc
V:EMN
|
$11.36 Million |
|
Baillie Gifford US Growth Trust PLC
LSE:USA
|
$11.36 Million |
|
Magna Terra Minerals Inc
V:MTT
|
$11.37 Million |
|
Magnum Mining and Exploration Ltd
AU:MGU
|
$11.37 Million |
|
Serica Energy PLC
LSE:SQZ
|
$11.36 Million |
|
Alligator Bioscience AB
ST:ATORX
|
$11.36 Million |
|
Indonesian Tobacco Tbk PT
JK:ITIC
|
$11.36 Million |
|
Advanced Packaging Tech (Malaysia)
KLSE:9148
|
$11.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IRLAB Therapeutics AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 32,634,000 to 30,718,000, a change of -1,916,000 (-5.9%).
- Net loss of 110,010,000 reduced equity.
- Share repurchases of 74,560,000 reduced equity.
- New share issuances of 74,560,000 increased equity.
- Other comprehensive income decreased equity by 1,000.
- Other factors increased equity by 108,095,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-110.01 Million | -358.13% |
| Share Repurchases | Skr74.56 Million | -242.72% |
| Share Issuances | Skr74.56 Million | +242.72% |
| Other Comprehensive Income | Skr-1.00K | -0.0% |
| Other Changes | Skr108.09 Million | +351.89% |
| Total Change | Skr- | -5.87% |
Book Value vs Market Value Analysis
This analysis compares IRLAB Therapeutics AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.71x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.60x to 2.71x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr2.07 | Skr1.24 | x |
| 2015-12-31 | Skr3.77 | Skr1.24 | x |
| 2016-12-31 | Skr4.03 | Skr1.24 | x |
| 2017-12-31 | Skr4.51 | Skr1.24 | x |
| 2018-12-31 | Skr5.46 | Skr1.24 | x |
| 2019-12-31 | Skr4.40 | Skr1.24 | x |
| 2020-12-31 | Skr7.30 | Skr1.24 | x |
| 2021-12-31 | Skr7.72 | Skr1.24 | x |
| 2022-12-31 | Skr5.61 | Skr1.24 | x |
| 2023-12-31 | Skr2.23 | Skr1.24 | x |
| 2024-12-31 | Skr0.63 | Skr1.24 | x |
| 2025-12-31 | Skr0.46 | Skr1.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently IRLAB Therapeutics AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -358.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -191.45%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 4.50x
- Recent ROE (-358.13%) is below the historical average (-82.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 6.17% | 5781.48% | 0.00x | 2.10x | Skr-1.93 Million |
| 2015 | -12.92% | -412.74% | 0.03x | 1.10x | Skr-21.09 Million |
| 2016 | -41.10% | -29650.00% | 0.00x | 1.09x | Skr-53.08 Million |
| 2017 | -36.27% | -51582.57% | 0.00x | 1.05x | Skr-71.72 Million |
| 2018 | -34.87% | -411661.11% | 0.00x | 1.06x | Skr-95.35 Million |
| 2019 | -52.97% | -370453.85% | 0.00x | 1.14x | Skr-114.50 Million |
| 2020 | -26.40% | -30616.00% | 0.00x | 1.06x | Skr-126.64 Million |
| 2021 | 12.96% | 24.92% | 0.44x | 1.18x | Skr11.83 Million |
| 2022 | -39.27% | -186.80% | 0.19x | 1.11x | Skr-143.29 Million |
| 2023 | -153.62% | -3132.07% | 0.03x | 1.53x | Skr-189.42 Million |
| 2024 | -254.73% | -87.85% | 0.69x | 4.17x | Skr-86.39 Million |
| 2025 | -358.13% | -191.45% | 0.42x | 4.50x | Skr-113.08 Million |
Industry Comparison
This section compares IRLAB Therapeutics AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $159,185,570
- Average return on equity (ROE) among peers: -26.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IRLAB Therapeutics AB (publ) (IRLAB-A) | Skr30.72 Million | 6.17% | 3.50x | $11.36 Million |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $5.16 Million |
| Ascelia Pharma AB (publ) (ACE) | $237.06 Million | -16.83% | 0.06x | $41.03 Million |
| AcouSort AB (ACOU) | $376.48K | 28.69% | 1.44x | $9.52 Million |
| Active Biotech AB (ACTI) | $46.67 Million | -106.88% | 0.22x | $103.60 Million |
| Alzinova AB (ALZ) | $105.53 Million | -12.38% | 0.06x | $8.00 Million |
| AlzeCure Pharma (ALZCUR) | $233.17 Million | -15.43% | 0.02x | $46.62 Million |
| Annexin Pharmaceuticals AB (ANNX) | $15.57 Million | -63.12% | 0.51x | $9.23 Million |
| Alligator Bioscience AB (ATORX) | $41.44 Million | 0.00% | 0.15x | $11.36 Million |
| BioInvent International AB (BINV) | $49.01 Million | -36.81% | 0.66x | $163.58 Million |
| BioArctic AB (publ) (BIOA-B) | $788.68 Million | -15.19% | 0.14x | $2.39 Billion |
About IRLAB Therapeutics AB (publ)
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pir… Read more